Journal
ONCOTARGET
Volume 8, Issue 52, Pages 90521-90531Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19361
Keywords
chimeric antigen receptor; T cells; cancer; adoptive cell transfer; tumor microenvironment
Categories
Funding
- National Key Research and Development Program of China [2016YFC0905900]
- National Natural Science Foundation [81430062]
- Priority Academic Program of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have been shown to have unprecedented efficacy in B cell malignancies, most notably in B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate using anti-CD19 CAR-T cells. However, CAR T-cell therapy for solid tumors currently is faced with numerous challenges such as physical barriers, the immunosuppressive tumor microenvironment and the specificity and safety. The clinical results in solid tumors have been much less encouraging, with multiple cases of toxicity and a lack of therapeutic response. In this review, we will discuss the current stats and challenges of CAR-T cell therapy for solid tumors, and propose possibl e solutions and future perspectives.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available